• Six clinical trials on MSCs approved by US FDA
    Six clinical trials on MSCs approved by US FDA
  • One of the few companies manufacturing both hMSC and hNSC
    One of the few companies manufacturing both hMSC and hNSC
  • First FDA-approved clinical trial using stem cells to treat Alzheimer’s
    First FDA-approved clinical trial using stem cells to treat Alzheimer’s
  • MSCs approved as a treatment of AMI in Kazakhstan
    MSCs approved as a treatment of AMI in Kazakhstan
  • Producing clinical-grade stem cells with strong activity in large scale
    Producing clinical-grade stem cells with strong activity in large scale
  • SCF activity preserved through patented technology for 3 years
    SCF activity preserved through patented technology for 3 years

Add:21st Floor, Block 1, Jusha Center, No.16 Xinyuanli, Chaoyang District, Beijing

Phone: 86-10-64654791

 

 

Copyright ©Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.! 

京ICP备19006400号-1     Powered by 300.cn

News Center

Jiuzhitang Maker signed the Cooperation Agreement on Jointly Building Jiuzhitang-ALTACO International Medical center for Stem Cells with Kazakhstan-based LLP "ALTACO-XXI" in the China-Kazakhstan Horgos Frontier International Cooperation Center.

Page view:

On January 23, 2019, Jiuzhitang Maker signed the Cooperation Agreement on Jointly Building Jiuzhitang-ALTACO International Medical center for Stem Cells with Kazakhstan-based LLP "ALTACO-XXI" in the China-Kazakhstan Horgos Frontier International Cooperation Center. The purpose of establishing this medical center is to promote application of stem cell drugs and collaboration on clinical research projects. This move signifies Jiuzhitang’s stem cell products will enter the stage of commercial operation, making it the first to achieve commercialization among domestic competitors.